PurePlay AI and PurpleLab launch mid-funnel pharma measurement tool

PurePlay AI and PurpleLab have launched Embedded Pulse, a direct-API integration that gives pharma marketers same-day, impression-level attribution and a new patient-visit metric for campaign optimization. The system is already live with early results across HCP and DTC campaigns, and Klick Health is the first agency to use it for direct-to-consumer media.

Why it matters: - Pharma marketers have long faced a timing gap between audience-quality signals that arrive too early and prescription lift data that arrives months later. - Embedded Pulse is designed to fill that gap with a mid-funnel KPI that can guide in-flight optimization and stand up to brand-team scrutiny. - The integration also aims to replace token-chain workflows and post-flight reconciliation with same-day attribution at the impression level.

What happened: - PurePlay AI announced Embedded Pulse with PurpleLab, a healthcare analytics company with real-world data across more than 330 million U.S. patient lives and 3 million-plus HCPs. - The launch took place July 9, 2026, in New York. - The integration uses PurpleLab’s identity resolution technology through a direct API. - PurePlay paired Embedded Pulse with PurpleLab’s newly launched Eligibility Alerts. - Klick Health is the first agency to deploy Embedded Pulse for direct-to-consumer pharma media.

The details: - Embedded Pulse delivers 24-hour Rx attribution at the impression level. - The system provides patient-visit measurement as a mid-funnel KPI between audience quality and prescription lift. - Eligibility Alerts surfaces four to seven days of pre-visit intelligence from healthcare eligibility verification transactions. - PurePlay says the integration compresses identity resolution from days to hours. - The pipeline uses PurpleLab APIs for Audience Quality scoring, Script Lift and HCP Visit measurement. - PurePlay’s scoring engine evaluates each impression against 20 signals. - The optimization loop uses aggregated signals including domain, geo, daypart, device, IAB category and supply path. - Top-performing slices get bid floors raised, while underperformers get throttled. - The system retrains on a weekly cadence. - PurePlay’s exposure data goes into PurpleLab’s HIPAA-compliant environment for de-identified matching, and no PHI enters PurePlay’s infrastructure. - PurePlay says its compliance posture aligns with the NIST Cybersecurity Framework and NIST AI Risk Management Framework, and its methodologies are HIPAA, IAB and NAI compliant. - Embedded Pulse is available now to PurePlay and PurpleLab clients. - Curated deals are live across multiple SSP partners, with expansion planned through Q3 2026.

Between the lines: - The launch reflects a push in pharma ad tech toward deterministic measurement that can influence campaigns before the budget is spent. - The combination of claims data, identity resolution and visit-level signals is meant to make optimization more actionable than audience scoring alone. - Early validation against actual prescription claims suggests the product is being positioned as a replacement for panel-based modeling and delayed post-campaign readouts. - The timing also shows how health-data vendors are moving deeper into media activation, not just reporting.

What's next: - PurePlay plans to broaden deployment across its client roster. - Embedded Pulse will continue expanding through Q3 2026. - The companies are likely to use the early HCP and DTC results as proof points for additional agency and brand adoption.

The bottom line: - PurePlay AI and PurpleLab are trying to make pharma media measurable while campaigns are still live, not weeks or months later.